This database contains 40 studies, archived under the term: "Sweden"
Click here to filter this large number of results.
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]
Effect of a high-intensity functional exercise program on functional balance: preplanned subgroup analyses of a randomized controlled trial in residential care facilities
Littbrand, Håkan,
Carlsson, Maine,
Lundin-Olsson, Lillemor,
Lindelöf, Nina,
Håglin, Lena,
Gustafson, Yngve,
Rosendahl, Erik
Objectives: To evaluate whether age, sex, depression, dementia disorder, nutritional status, or level of functional balance capacity influences the effect of a high-intensity functional weight-bearing exercise program on functional balance.; Design: Preplanned subgroup analyses of a randomized controlled trial.; Setting: Nine residential care facilities.; Participants: One hundred ninety-one people aged 65 to 100 dependent in […]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment
Johansson, C.,
Ballard, C.,
Hansson, O.,
Palmqvist, S.,
Minthon, L.,
Aarsland, D.,
Londos, E.
Objective: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to […]
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study
Faxén Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Brismar, Kerstin,
Hjorth, Erik,
Palmblad, Jan,
Vessby, Bengt,
Vedin, Inger,
Wahlund, Lars-Olof,
Cederholm, Tommy
Objectives: To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer’s disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4).; Design: Randomized, double-blind, placebo-controlled trial.; Setting: Specialist memory clinics in the Stockholm catchment area.; Participants: Two hundred four patients (aged […]
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Faxén-Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Hjorth, Erik,
Palmblad, Jan,
Vedin, Inger,
Cederholm, Tommy,
Wahlund, Lars-Olof
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]
Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins
Brommelhoff, Jessica A.,
Gatz, Margaret,
Johansson, Boo,
McArdle, John J.,
Fratiglioni, Laura,
Pedersen, Nancy L.
This study tested whether history of depression is associated with an increased likelihood of dementia, and whether a first depressive episode earlier in life is associated with increased dementia risk, or whether only depressive episodes close in time to dementia onset are related to dementia. Depression information came from national hospital discharge registries, medical history, […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]